SOURCE: MMIT Analytics, as of 5/30/19
Monday, June 3, 2019
The FDA last week approved...
...Allergan's Vraylar for the depressive form of Bipolar I
disorder, making it the first drug approved to treat the full spectrum of
Bipolar I symptoms. For the treatment of manic or mixed bipolar depression,
Vraylar currently holds preferred status for 13% of covered lives, and is
classified as a specialty product for 8% of lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment